Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy
- PMID: 29930315
- DOI: 10.1038/s41577-018-0031-5
Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy
Abstract
In the initially published version of this article online in advance of print, a reference (Ajina, A. & Maher, J. Prospects for combined use of oncolytic viruses and CAR T-cells. J. Immunother. Cancer 5, 90 (2017)) was omitted in error from the following sentence: "The ability of oncolytic viruses to increase the expression of MHC class I molecules by cancer cells is also predicted to enhance ACT with TILs or TCR-engineered and chimeric antigen receptor (CAR) T cells that target tumour-specific antigens". This has been corrected in the HTML and PDF versions of the manuscript.
Erratum for
-
Integrating oncolytic viruses in combination cancer immunotherapy.Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6. Nat Rev Immunol. 2018. PMID: 29743717 Review.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials